Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda, Kyoto University to End T-CiRA iPS Cell Program after 10 Years
Quick Look: Takeda and Kyoto University will end their 10-year iPSC research collaboration in March 2026. Key assets have been transferred to outside partners as Takeda exits cell therapy, though a...
To read the full story
Related Article
- Alloy Inks Cell Therapy Deal with Takeda, Japan Outpost to Launch by Month-End
November 22, 2024
- Orizuru Therapeutics Boots Up to Take Over iPSC Assets from T-CiRA, Eyes IPO in 2026
August 11, 2021
- Takeda, Kyoto University Kick Off iPS Projects Targeting 6 Diseases
December 16, 2015
- Takeda’s iPS Cell Deal Potential Game Changer in Drug Research
April 20, 2015
- Takeda Hooks Up with Prof. Yamanaka on iPS Cell Research
April 17, 2015
BUSINESS
- Fuji Plans July Launch for Japan’s 1st Simponi, Ranmark Biosimilars
May 21, 2026
- Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
- Takeda Hit with Massive Damages Verdict in US Amitiza Antitrust Case
May 20, 2026
- Top Generic Makers Grow Sales on Higher Output, Shipment Recovery
May 20, 2026
- Tapinarof Cream Logs Positive Data in Infant Atopic Dermatitis: Shionogi
May 20, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…